J&J wraps up $2.1bn acquisition of Japanese cosmetics company Ci:z Holdings
US healthcare conglomerate Johnson & Johnson (J&J) completed its previously announced JPY230 billion ($2.1 billion) acquisition of Japanese cosmetics company Ci:z Holdings. Headquartered in Tokyo, ... Read More
Amgen submits BLA for Infliximab biosimilar ABP 710 to FDA
Amgen Inc. has officially submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to ... Read More
Esketamine nasal spray misses key trial expectations, but Janssen remains optimistic
Janssen Pharmaceutical Companies of Johnson & Johnson encountered a significant setback with their esketamine nasal spray in a phase 3 trial aimed at treating patients ... Read More
Janssen secures EC approval for daratumumab as new multiple myeloma therapy
The Janssen Pharmaceutical Companies of Johnson & Johnson have achieved a significant milestone with the European Commission's approval of Darzalex (daratumumab) for use as an ... Read More
Janssen Pharmaceutical’s IMBRUVICA and Rituximab combo wins FDA approval for waldenström’s macroglobulinemia treatment
Janssen Pharmaceutical, a subsidiary of Johnson & Johnson, has received approval from the US Food and Drug Administration (FDA) for its combination treatment of IMBRUVICA ... Read More